Acquired necrotizing myopathies

Current Opinion in Neurology

Volumn 26, Issue 5, 2013, Pages 554-560

  Allenbach, Yves ^a   Benveniste, Olivier ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; COMPLEMENT MEMBRANE ATTACK COMPLEX; CREATINE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; IMMUNOGLOBULIN; METHOTREXATE; PREDNISONE; RITUXIMAB; SIGNAL RECOGNITION PARTICLE;

ANTIBODY TITER; ARTHRALGIA; CORRELATIONAL STUDY; CORTICOSTEROID THERAPY; CREATINE KINASE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE COURSE; DYSPHAGIA; DYSPNEA; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR HISTOCOMPATIBILITY COMPLEX; MUSCLE BIOPSY; MUSCLE NECROSIS; MUSCULAR DYSTROPHY; MYOPATHY; NECROTIZING AUTOIMMUNE MYOPATHY; NEOPLASM; PLASMAPHERESIS; RAYNAUD PHENOMENON; REVIEW; RHABDOMYOLYSIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TOXIC NECROTIZING MYOPATHY;

AUTOANTIBODIES; AUTOIMMUNE DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MUSCULAR DYSTROPHIES; MYOSITIS;

EID: 84883800491     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328364e9d9     Document Type: Review

References (39)

1. Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004; 14:337-345.
2. Targoff IN, Johnson AE, Miller FW. Antibody to signal recognition particle in polymyositis. Arthritis Rheum 1990; 33:1361-1370.
3. Kao AH, Lacomis D, Lucas M, et al. Antisignal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 2004; 50:209-215.
4. Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statinassociated autoimmune myopathy. Arthritis Rheum 2011; 63:713-721.
5. Ellis E, Ann Tan J, Lester S, et al. Necrotizing myopathy: Clinico-serologic associations. Muscle Nerve 2012; 45:189-194.
6. Levin MI, Mozaffar T, Al-Lozi MT, Pestronk A. Paraneoplastic necrotizing myopathy: Clinical and pathological features. Neurology 1998; 50:764-767.
7. Brouwer R, Hengstman GJ, Vree Egberts W, et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001; 60:116-123.
8. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: Myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991; 70:360-374.
9. Christopher-Stine L, Casciola-Rosen LA, Hong G, et al. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immunemediated necrotizing myopathy. Arthritis Rheum 2010; 62:2757-2766.
10. Reeves WH, Nigam SK, Blobel G. Human autoantibodies reactive with the signal-recognition particle. Proc Natl Acad Sci U S A 1986; 83:9507-9511.
11. Hengstman GJ, ter Laak HJ, Vree Egberts WT, et al. Antisignal recognition particle autoantibodies: Marker of a necrotising myopathy. Ann Rheum Dis 2006; 65:1635-1638.
12. Suzuki S, Satoh T, Sato S, et al. Clinical utility of antisignal recognition particle antibody in the differential diagnosis of myopathies. Rheumatology (Oxford) 2008; 47:1539-1542.
13. Miller T, Al-Lozi MT, Lopate G, Pestronk A. Myopathy with antibodies to the signal recognition particle: Clinical and pathological features. J Neurol Neurosurg Psychiatry 2002; 73:420-428.
14. Rouster-Stevens KA, Pachman LM. Autoantibody to signal recognition particle in African American girls with juvenile polymyositis. J Rheumatol 2008; 35:927-929.
15. Dimitri D, Andre C, Roucoules J, et al. Myopathy associated with antisignal recognition peptide antibodies: Clinical heterogeneity contrasts with stereotyped histopathology. Muscle Nerve 2007; 35:389-395.
16. Shirai Y, Koizumi K, Ogawa R, et al. Antisignal recognition particle (SRP) antibody positive polymyositis refractory to corticosteroid treatment. Nihon Naika Gakkai Zasshi 2007; 96:2522-2524.
17. Vincze M, Molnar PA, Tumpek J, et al. An unusual association: Anti-Jo1 and anti-SRP antibodies in the serum of a patient with polymyositis. Clin Rheumatol 2010; 29:811-814.
18. Romisch K, Miller FW, Dobberstein B, High S. Human autoantibodies against the 54 kDa protein of the signal recognition particle block function at multiple stages. Arthritis Res Ther 2006; 8:R39.
19. Benveniste O, Drouot L, Jouen F, et al. Correlation of antisignal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum 2011; 63:1961-1971.
20. Arlet JB, Dimitri D, Pagnoux C, et al. Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromuscul Disord 2006; 16:334-336.
21. Valiyil R, Casciola-Rosen L, Hong G, et al. Rituximab therapy for myopathy associated with antisignal recognition particle antibodies: A case series. Arthritis Care Res (Hoboken) 2010; 62:1328-1334.
22. Grable-Esposito P, Katzberg HD, Greenberg SA, et al. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 2010; 41:185-190.
23. Allenbach Y, Rigolet A, Drouot L, et al. Autoimmune necrotizing myopathies with anti-HMGCR antibodies are related to statin exposure only for a minority of cases. WMS Congress in Asilomar Conference Grounds, California, USA; 2013.
24. Mammen AL, Pak K, Williams EK, et al. Rarity of anti3-hydroxy-3- methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res (Hoboken) 2012; 64:269-272.
25. Mammen AL, Gaudet D, Brisson D, et al. Increased frequency of DRB1-11:01 in antihydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Care Res (Hoboken) 2012; 64:1233-1237.
26. Werner JL, Christopher-Stine L, Ghazarian SR, et al. Antibody levels correlate with creatine kinase levels and strength in anti3-hydroxy-3- methylglutarylcoenzyme A reductase-associated autoimmune myopathy. Arthritis Rheum 2012; 64:4087-4093.
27. Ranque B, Authier FJ, Le-Guern V, et al. A descriptive and prognostic study of systemic sclerosis-associated myopathies. Ann Rheum Dis 2009; 68:1474-1477.
28. Koschik RW 2nd, Fertig N, Lucas MR, et al. Anti-PM-Scl antibody in patients with systemic sclerosis. Clin Exp Rheumatol 30 (Suppl 71):S12-S16.
29. Ranque B, Berezne A, Le-Guern V, et al. Myopathies related to systemic sclerosis: A case-control study of associated clinical and immunological features. Scand J Rheumatol 2010; 39:498-505.
30. Smith B. Skeletal muscle necrosis associated with carcinoma. J Pathol 1969; 97:207-210.
31. Bronner IM, Hoogendijk JE, Wintzen AR, et al. Necrotising myopathy, an unusual presentation of a steroid-responsive myopathy. J Neurol 2003; 250:480-485.
32. Emslie-Smith AM, Engel AG. Necrotizing myopathy with pipestem capillaries, microvascular deposition of the complement membrane attack complex (MAC), and minimal cellular infiltration. Neurology 1991; 41:936-939.
33. Sampson JB, Smith SM, Smith AG, et al. Paraneoplastic myopathy: Response to intravenous immunoglobulin. Neuromuscul Disord 2007; 17:404-408.
34. Benveniste O, Romero NB. Myositis or dystrophy?. Traps and pitfalls. Presse Med 2011; 40:249-255.
35. Hicks D., Sarkozy A., Muelas N., et al. A founder mutation in Anoctamin 5 is a major cause of limb-girdle muscular dystrophy. Brain 2011; 134:171-182.
36. Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis: An evaluation of 475 hospitalized patients. Medicine (Baltimore) 2005; 84:377-385.
37. Gaist D, Rodriguez LA, Huerta C, et al. Lipid-lowering drugs and risk of myopathy: A population-based follow-up study. Epidemiology 2001; 12:565-569.
38. Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statin-related adverse events: A meta-analysis. Clin Ther 2006; 28:26-35.
39. Kuncl RW. Agents and mechanisms of toxic myopathy. Curr Opin Neurol 2009; 22:506-515.